News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Gilberto Lopes: In phase 3 EVOKE-01 study improvement of OS was noted in patients without response to prior IO
Photo generated from meetings.asco.org
Jun 3, 2024, 13:08

Gilberto Lopes: In phase 3 EVOKE-01 study improvement of OS was noted in patients without response to prior IO

Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared a post on X:

“LBA out: Phase 3 EVOKE-01 study. Sacituzumab vs Docetaxel… and… no better! Underwhelming results. One subgroup to note ‘Clinically meaningful improvement of OS was noted in patients without response to prior IO’. 383 patients OS 8.3 vs 11.8 for these patients HR 0.75 (0.58–0.97).”

Image

Read further
Source: Gilberto Lopes/X

2024 Annual Meeting of ASCO 3 EVOKE-01 ASCO24 cancer docetaxel Gilberto Lopes IO therapy LBA OncoDaily Oncology Sacituzumab
Special Coverage
Science
Aug 8, 2025, 05:01
Arndt Vogel: ESMO-MCBS 2.0 Scorecards for Hepatocellular Carcinoma
Oncolibrary
Aug 8, 2025, 03:13
CAR T-Cell Therapy vs iNKT Cell Therapy: The Future of Engineered Immune Cells in Cancer Treatment
Oncolibrary
Aug 8, 2025, 03:09
Immunotherapy for Cancer Success Rate: What Patients Need to Know in 2025
Oncolibrary
Aug 8, 2025, 01:07
10-Minute Immunotherapy Infusion: Safe, Efficient Delivery of Nivolumab and Pembrolizumab
Societies
Aug 7, 2025, 23:50
Because Every Patient Matters: Promoting Diversity in Cancer Support - MASCC
Blog
Aug 7, 2025, 22:17
Arif Kamal: ACS is Celebrating 60 Years of Community-Driven Primary Care at Health Centers
Blog
Aug 7, 2025, 21:48
Michael Ziener: NFL and ACS Join Forces to Expand Cancer Screening Access
Blog
Aug 7, 2025, 21:02
John V. Oyler: Q2 2025 Marks Another Strong Quarter for BeOne Medicines
Insight
Aug 7, 2025, 20:53
Luke Dow: The Complexity of Drug Resistance in Colorectal Cancer
Career
Aug 7, 2025, 20:24
Elizabeth Ugwoma Awo-Ejeh: Grateful to Have Been Selected as One of the Dicey Scroggins Patient Advocacy Fellows
Blog
Aug 7, 2025, 20:07
MaryRose Mazzola: $130K Raised for the Dana-Farber Cancer Institute and The Scars Foundation
Blog
Aug 7, 2025, 19:57
Carmen Monge-Montero: Where You're Born Should not Determine if You Survive